No Data
Piper Sandler Maintains Quest Diagnostics(DGX.US) With Hold Rating, Raises Target Price to $200
Fitch Elevates Quest Diagnostics' Rating to 'BBB+' With Stable Outlook
Express News | Piper Sandler Maintains Neutral on Quest Diagnostics, Raises Price Target to $200
Goldman Sachs: The Q1 performance of U.S. pharmaceutical stocks is reassuring, and the Industry sentiment is slightly becoming more positive.
Goldman Sachs stated that amid cautious sentiment from investors towards the USA pharmaceutical sector before the Earnings Reports season, the performance of USA pharmaceutical companies that have reported results so far for the first quarter has not been worse than expected, and in some cases, it has even exceeded expectations.
The Trump administration plans to impose tariffs on imported Pharmaceuticals, and the U.S. Pharmaceutical Industry warns that it may increase drug costs.
A report commissioned by a trade organization in the USA Pharmaceutical Industry indicates that if the USA imposes a 25% tariff on imported Pharmaceuticals, it could increase the annual Pharmaceutical costs in the USA by nearly 51 billion dollars and raise drug prices by up to 12.9%.
Here's How Much You Would Have Made Owning Quest Diagnostics Stock In The Last 5 Years
